Opendata, web and dolomites

EFOEUPATI SIGNED

Ensuring the future of EUPATI beyond 2020

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EFOEUPATI" data sheet

The following table provides information about the project.

Coordinator
FORUM EUROPEEN DES PATIENTS (FPE) 

Organization address
address: RUE DICKS 14
city: LUXEMBOURG
postcode: 1417
website: http://www.eu-patient.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Luxembourg [LU]
 Project website http://www.eupati.eu/efoeupati/
 Total cost 604˙042 €
 EC max contribution 365˙242 € (60%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-11-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) coordinator 188˙340.00
2    IRISH PLATFORM FOR PATIENTS' ORGANISATIONS SCIENCE AND INDUSTRY LIMITED BY GUARANTEE IE (DUBLIN) participant 97˙188.00
3    EUROPEAN AIDS TREATMENT GROUP EV DE (DUSSELDORF) participant 61˙237.00
4    EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE BE (BRUSSELS) participant 14˙726.00
5    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 3˙750.00
6    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
7    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
8    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
9    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
10    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
11    PFIZER LIMITED UK (SANDWICH) participant 0.00
12    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

The European Patients' Academy on Therapeutic Innovation (EUPATI) IMI project resulted in a number of key outputs for the field of patient engagement. The core activities continue running until 2019 under a PPP consortium under an EPF programme focusing on the Patient Expert Training Course, the multilingual public Toolbox, and the EUPATI National Platforms Network. It is imperative that these pillars that support the patient engagement landscape exist in the medium- and long-term to address the growing field of patient engagement. Further investment is needed to develop sustainable models of collaboration to ensure this, and put into place the infrastructure required for these to work, building on those already established under IMI-EUPATI.

 Deliverables

List of deliverables.
Report on user & functional requirement of patient education and engagement portal. Open Research Data Pilot 2020-04-14 17:17:11
Report on the WP2-WP4 workshop Documents, reports 2020-04-14 17:17:11
Progress report on design & implementation of Patient Education and Engagement Portal. Documents, reports 2020-04-14 17:17:11
Governance Plan Documents, reports 2020-04-14 17:17:11

Take a look to the deliverables list in detail:  detailed list of EFOEUPATI deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EFOEUPATI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EFOEUPATI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More